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Members of the large multigene family of acyl-CoA binding domain containing proteins 
(ACBDs) share a conserved motif required for binding of Coenzyme A esterified fatty acids of 
various chain length. These proteins are present in the three kingdoms of life, and despite their 
predicted roles in cellular lipid metabolism, knowledge about the precise functions of many 
ACBD proteins remains scarce. Interestingly, several ACBD proteins are now suggested to 
function at organelle contact sites, and are recognized as host interaction proteins for different 
pathogens including viruses and bacteria. Here, we present a thorough phylogenetic analysis 
of the ACBD family and discuss their structure and evolution. We summarize recent findings 
on the various functions of animal and fungal ACBDs with particular focus on peroxisomes, 
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 Acyl-CoA binding domain-containing proteins (ACBDs) can be found among 
eukaryotes and prokaryotes. 
 Additional protein interaction domains are a characteristic of most extended ACBDs. 
 A set of a small ACBD and an ACBD with a C-terminal ankyrin-repeat motif is found 
in all eukaryote branches. 
 Fungi and metazoans contain genes for ACBD5/ATG37 but the proteins do not 
appear to possess conserved functions 
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 Several extended metazoan ACBDs are hijacked by viruses in order to facilitate 








Acyl-CoA binding domain containing proteins (ACBDs) comprise a large multigene family of 
diverse proteins that are defined by the presence of a conserved 80 residues-long acyl-CoA 
binding motif (ACB) [1,2]. Activated fatty acids play important roles as lipid metabolites, but 
also in the regulation of lipid metabolism and in cellular signaling [1,3], and ACBD proteins 
fulfill important functions in controlling their concentration. In mammals, seven ACBD 
proteins (ACBD1-7) have been specified so far (see section 1. for ACBD8), often with 
different transcript variants [1]. Those include small, soluble proteins (ACBD1, ACBD7), but 
also large, multifunctional enzymes (ACBD2), membrane proteins (ACBD4, ACBD5), and 
proteins with a GOLD (Golgi dynamics)-domain (ACBD3) or ankyrin repeats (ACBD6). 
Homologous ACBD proteins are found in animals, plants and fungi, but also in bacteria and 
archea (see section 1.). Despite their predicted roles in cellular lipid metabolism, the functions 
of many of the ACBD proteins still remain unclear. Interestingly, several of the ACBD proteins 
have recently been linked to peroxisome function [4–10]. Peroxisomes are ubiquitous 
membrane-bound organelles with key roles in lipid metabolism, including the breakdown and 
detoxification of fatty acids (via fatty acid α- and β-oxidation), and the synthesis of ether-
phospholipids (e.g. plasmalogens enriched in myelin sheaths), bile acids and polyunsaturated 
fatty acids (PUFAs) such as docosahexaenoic acid in humans. Defects in peroxisome 
biogenesis and metabolic function cause severe disorders with developmental and neurological 
defects [11–13]. Peroxisomal lipid metabolism requires cooperation and interaction with other 
organelles such as the endoplasmic reticulum (ER), mitochondria or lipid droplets [14]. Those 
peroxisome-organelle interactions are mediated by membrane contact sites (MCSs), which 
involve membrane-bound tether proteins to bring organelles in close apposition [15–17]. 
ACBD2, ACBD4, ACBD5 are now suggested to function as peroxisome-organelle tethers thus 
contributing to the formation of lipid hubs which facilitate lipid metabolism at the organelle 
interface [17]. ACBD3 was reported to function at Golgi-ER contact sites [18]. Importantly, 
organelle-associated ACBDs are now increasingly recognized as targets for different pathogens 
including viruses, Salmonella and Chlamydia [19–22]. These recent discoveries underline that 
ACBD proteins may have evolved to fulfill functions other than acyl-CoA buffering. Based on 
a comprehensive phylogenetic analysis, we will discuss the evolution of the structurally diverse 
ACBD proteins and will summarize their functions. We will also focus on the functions of 





1. Structure and evolution of the ACBD family 
 
1.1 Structure and function of the ACB core domain 
The ACB domain is a phylogenetically very ancient protein structure, which is found in all 
eukaryote branches. ACBDs which only carry the ACB domain are small proteins (≈10-15kDa) 
and are distributed among metazoans, fungi and plants, but are also found in eubacteria and 
archaea (see below). Thus, in general they appear to be the origin of all further extended forms 
of the protein family. In animals, these ACBD forms are represented by the acyl-CoA binding 
protein ACBD1 (ACBP, DBI), which preferentially binds long-chain acyl-CoAs [23,24]. 
Structurally, the ACB domain consists of a bundle of four α-helices. They form a bowl-like 
structure which has a largely non-polar cavity, lined by polar amino acids [25,26]. In its 
monomeric form, the acyl-chain is located in a bent conformation inside the cavity and is 
covered by the CoA group shielding it from the surrounding solvent [25]. When two ACBD1 
are assembled into a dimer, the 3’-phosphate-AMP moiety of acyl-CoA is bound in the binding 
pocket of one ACBD1 molecule and the acyl chain is bound in the pocket of the other ACBD1 
molecule [27]. According to the domain structures available at the Protein Data Bank [28], the 
ACB domain structures from small and extended ACBD proteins are conserved to a large 
extent. However, the individual ACBDs show particular variations in helix conformational 
assembly suggesting distinctly modified binding pockets which might result in differences in 
substrate specificities [29].  
Functionally, the small soluble forms may act as acyl-CoA transporters and reservoirs, 
guaranteeing efficient provision and targeting of acyl-CoA to lipid metabolizing subcellular 
compartments. For example, earlier theoretical calculations on the cytosolic free and protein-
bound concentrations of long-chain fatty acid (LCFA)-CoA imply that the predominant 
proportion of LCFA-CoA is bound to proteins with acyl-CoA binding capacity and potentially 
mainly to ACBD1 [30]. In this regard, ACBD1 may: i) stabilize LCFA-CoA preventing auto- 
or enzymatic hydrolysis [31,32], ii) prevent LCFA-CoAs from partitioning into cellular lipid 
bilayers, iii) extract membrane-inserted LCFA-CoAs for delivery to cellular sites of lipid 
metabolism, iv) hand over LCFA-CoAs to respective metabolizing enzymes or v) control 
stimulatory/inhibitory effects of LCFA-CoAs on lipid metabolizing proteins or lipid-binding 
receptors [30,33,34]. While these all seem logical roles, direct evidence in complex biological 
systems is lacking. After their formation by acyl-CoA synthetases [35], acyl-CoAs are either 
used for the generation of triglycerides and membrane lipids (e.g. phospholipids), for fatty acid 
elongation (e.g. to generate PUFAs), or degraded via mitochondrial or peroxisomal β-oxidation 
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and are thus distributed between a set of pools in the cell, including membranes, lipid droplets, 
and other lipid binding proteins. As evidenced by previous and our own phylogenetic 
reconstructions [36], during the evolution of eukaryotes, these small ACBDs evolved by 
genomic and structural variation to include different C-terminal or N-terminal extensions. 
These extended ACBD proteins acquired diverse functions and subcellular locations (Table 1, 
2). It can be speculated that such extensions might have been driven by a need to link the ACB 
domains to specific cellular locations (membranes, proteins, organelles) and locally control 
acyl-CoA concentration as required by metabolic pathways or regulate the function of proteins 
present at those locations.  
 
1.2 Small ACBD containing proteins 
In order to recapitulate the structural and functional evolution from the small ACBDs to the 
extended ACBD proteins we performed a phylogenetic analysis of 449 complete, ACBD-
containing sequences from 116 animal, plant and fungal species extracted from GenBank and 
the JGI Genome Portal (Fig. 1, Fig. S1). According to our analysis, most species possess at 
least one small (non-membrane anchored/soluble) ACBD with a mass of approximately 10 
kDa, and a tendency to accumulate several small forms in the genome can be observed 
throughout all organismal classes (Fig. 1). The origin of the small forms in plants, where the 
small ACBDs are termed ACBP class I, and in fungi could not be clearly resolved. They may 
have arisen polyphyletically by species-specific gene duplications or domain loss from 
extended forms. However, vertebrates developed two small, more closely related forms, 
ACBD1 and ACBD7, from a single invertebrate precursor. A third group of mammalian, small 
ACBD sequences form an individual branch on the cladogram (Fig. 1, Fig. S1). This third 
small ACBD form (in the following termed ACBD8) was originally identified as testis-specific 
endozepine-like peptide (ELP) in mice [37]. In humans the protein was not found to be 
expressed but still exists as pseudogene in the genome [38]. As the limited number of vertebrate 
species used in our initial phylogenetic analysis did not allow us to discriminate whether these 
three small ACBD variants descended from a single ancestor, we refined our analysis for the 
small forms. To this end, we restricted cladogram reconstruction to 246 sequences from 77 
metazoan species using the nearest neighbor ACBD2 cluster from our initial analysis as an 
outgroup (Fig. S2). According to the phylogenetic tree, there is evidence that the ancestor 
ACBD was duplicated into ACBD1 and ACBD7 during early vertebrate evolution, followed 
by a second gene duplication into ACBD8. Interestingly, proteins related to ACBD8 exist in 
the more primitive reptilian groups of crocodiles and turtles, suggesting that this event occurred 
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already at an earlier stage of amniotic evolution. Like in humans, predicted potential full-length 
ACBD8 protein sequences could not be retrieved from insectivoras, monotremata (mammalia), 
squamata (reptilia) and birds arguing for multiple evolutionary losses of a protein with a 
specialized or tissue-confined function. 
Unexpectedly, a significant number of small ACBD-like sequences were detected among 
prokaryotes during the searches (distributed in 108 bacterial genera). Thus, to unravel if the 
small ACBDs might have appeared already before the origin of eukaryotes, Blast-searches 
among all major prokaryote branches were performed. Indeed, numerous ACBD-like 
sequences with significant similarities could be retrieved (see Fig. S3 for sequence comparison) 
and were used for a phylogenetic reconstruction. As no extended forms were found among 
prokaryotes, the small forms from eukaryotes were routed with the prokaryotic sequences using 
the animal ACBD2 cluster as outgroup. Remarkably, the ACBDs from the major prokaryotic 
organism groups of archaea, β-, γ-, δ-proteobacteria and bacteroidetes clustered into individual 
distinct branches in parallel to the eukaryotic clades, while the rare sequences found in α-
proteobacteria did not align in a single branch but distributed as orphan sequences among the 
branches of the tree (Fig. S4). To further evaluate if the prokaryotic sequences could 
theoretically assemble into an ACBD structure, Phyre2 was used to predict potential tertiary 
protein conformations of selected prokaryotic and eukaryotic ACBD sequences [39]. As 
depicted in Fig. 2, all sequence models can theoretically form the 4 helix bundle structure 
typical for ACB domains. Remarkably, hydrophilic and hydrophobic patches on the protein 
surface like the hydrophobic acyl chain binding cleft between A2 and A3 or Phe5 and Tyr73 
for adenine binding [36] are also structurally conserved in all 3D predictions. As the possibility 
of numerous horizontal gene transfers in prokaryotes does not allow a simple cladistics 
reconstruction of bacterial protein evolution, it is not possible to speculate on the phylogeny of 
ACBDs in bacteria [40]. The occurrence of structurally homoform ACBD sequences in many 
prokaryote groups suggests that a common ancestor of the small ACBDs may have already 
arisen before appearance of the first eukaryotes. However, it cannot be excluded that multiple 
individual lateral gene transfers may have distributed the small ACBD sequences among the 
different prokaryote groups. 
With respect to their intracellular localization, the small ACBDs appear to reside in the cytosol 
but might associate temporarily with specific subcellular structures or may even be secreted 
[1,2]. Thus, their intracellular location may reflect the function of the small ACBDs as 





1.3 Extended ACBD containing proteins 
Based on the structure and motifs of the different accessory sequences in the extended ACBDs 
and the phylogenetic reconstruction, animal ACBD proteins can be classified into three 
additional principal protein groups: the tail-anchored ACBD proteins with a C-terminal α-
helical membrane anchor, the enzyme-coupled ACBDs and the extended, soluble forms with 
C-terminal interaction domains (Fig. 1, Fig. 3). In the heterogeneous group of extended, 
soluble ACBD forms, ankyrin-repeat motifs, which are positioned downstream of the ACB 
domain, are frequently found and also appear in the choanoflagellate Monosiga, the 
amoebozoan Dictyostelium and in planta but also among fungi in Basidiomycota and some of 
the early branching groups like e.g. Mucoromycotina. Unfortunately, the low sequence 
similarity and restricted availability of genomes in the more primitive plant, fungal, and animal 
classes prevented a full resolution of the evolutionary radiation of these extended ACBD 
subfamilies (Fig S1). Nevertheless, based on the structural conservation among all different 
phyla it can be assumed that the ankyrin-repeat containing ACBDs, which in animals are 
represented by ACBD6, may have already developed in the last eukaryotic common ancestor 
(LECA).  
Plant ACBPs have been grouped into the ACBP classes I-IV, which consist of the ACBP class 
I (10 kDa form) and the larger, extended forms from class II-IV [41]. For easier discrimination, 
we will hence term metazoan and fungal ACB-domain containing proteins according to the 
ACBD nomenclature and the plant forms as ACBP class I-IV. In plants, ankyrin-repeat 
containing ACBD proteins are classified as the ACBP class II [2], which clusters in proximity 
to the ACBD6 group in the phylogenetic reconstruction (Fig. 1). Compared to the animal and 
fungal ankyrin-repeat containing ACBD6 proteins, the plant ACBP IIs are larger proteins with 
an additional N-terminal extension bearing a transmembrane helix (TMD) which may also act 
as a signal sequence for subcellular targeting [41] (Fig. 3). The plant ACBP class III is closely 
related to class II, also exhibiting an N-terminal TMD and an ACB domain, however, it lacks 
the C-terminal ankyrin-repeat motifs (Fig. 3). Thus, if the fusion of the ankyrin and ACB 
domains did not occur by convergent evolution in metazoans, plants and fungi, plant ACBP 
class III may have evolved from class II by secondary loss of this motif. The important 
structural difference of the additional TMD in plants is further demonstrated by the different 
subcellular localization of ankyrin-repeat containing ACBDs in animals and plants. While 
under normal conditions ACBD6 is a soluble protein locating to the cytosol and nucleus [19], 
plant ACBP class II and class III proteins are membrane-anchored and were found at the ER, 
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Golgi and plasma membrane [2]. Functionally, ankyrin-repeats are typical protein structures 
facilitating protein interactions, however, they were also recently found to mediate lipid 
binding at subcellular membranes [42]. Thus, ankyrin-repeats of ACBP II/ACBD6 proteins 
might mediate temporary contacts with intracellular membranes, either directly or via 
interaction with a transmembrane protein.  
In addition to the ACBPs with C-terminal ankyrin-repeats, C-terminal Kelch motifs and GOLD 
(Golgi dynamics) domains can be found in plants and metazoans including choanoflagellates, 
respectively (ACBP IV, ACBD3) (Fig. 3). Both groups may have independently evolved; 
according to sequence similarities and routing in the ACBD3 branch of the cladogram, 
however, they may share a common extended ACBD ancestor protein (Fig. 1, Fig. S1). 
ACBD3 is structurally related to ACBD6, but instead of ankyrin-repeats the protein possesses 
a β-strand-rich GOLD domain in its C-terminal region, which can facilitate interactions with 
other proteins and may be used to stabilize peripheral membrane proteins at intracellular 
membranes [43] (Fig. 3). In addition, ACBD3 exhibits a highly conserved coiled-coil region 
located in the middle of the sequence, which might act as another protein interaction domain. 
Unlike ACBD6, ACBD3 can only be found in animals and choanoflagellates and thus appears 
to have evolved comparatively late. ACBD3 localizes to the ER/Golgi intermediate 
compartment facilitating important functions in vesicle trafficking, as well as at mitochondria 
[46]. Since GOLD domains can be found in several lipid binding or lipid transport proteins 
such as the tocopherol associated proteins, the FYVE finger domain containing proteins or the 
oxysterol-binding proteins [43,44], GOLD domain containing proteins such as ACBD3 might 
regularly assist in lipid/vesicle transfer at intracellular membranes. Kelch repeats of the plant 
ACBP class IV, which form a β-propeller protein domain fold, are also typical structures 
mediating protein interactions [45]. Like ACBD3, the plant class IV ACBPs possess additional 
conserved coiled-coil motifs. However, as those are located at the very most C-terminal part of 
the proteins after the Kelch repeats, this seems to be a convergent evolution event combining 
two protein interaction domains (Fig. 3). Most Kelch repeat containing ACBPs seem to localize 
to the cytosol, where they might temporarily associate with various intracellular membrane 
structures; but ACBP6 of the Asian rice Oryza sativa was recently found to reside at 
peroxisomes where it may cooperate in peroxisomal fatty acid β-oxidation [46]. 
In addition to the ACBD3/6 branch, our phylogenetic reconstruction shows two further clusters 
of extended ACBDs, which are restricted to fungi and metazoans (ACBD4/5) or only 
metazoans (ACBD2). ACBD5, which in fungi was termed Atg37 [47], consists of an N-
terminal ACB domain, a C-terminal TMD and three structures suited for mediating protein 
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interactions: a FFAT (two phenylalanines (FF) in an acidic tract) and two coiled coil motifs in 
the intermediate part of the protein (Fig. 3). ACBD4 is a structurally and phylogenetically 
closely related protein with the same domain arrangement (Fig. 3). However, ACBD4s are 
significantly more compact proteins which appear to have evolved from ACBD5 by a later 
gene duplication, which only occurred in vertebrates (Fig. 1). Using a FFAT motif prediction 
tool (with a cut-off FFAT score ≤2.5) [48], we checked for the presence of predicted FFAT 
motifs in ACBD4/5/Atg37 proteins used in our phylogenetic analysis and identified a FFAT 
motif in almost all (89%) of the animal ACBD4/5 proteins. By contrast, the motif was not 
found in the majority of fungal species analysed but interestingly did appear in several cases 
(12.5%) (Table S1). To investigate this further, we extended our analysis to include 161 fungal 
species where we could identify a clear ACBD5 orthologue (Atg37) and also performed 
randomised sequence comparisons, applying a simple statistical analysis (as used in [49]) to 
control for false positives. Here, we observed an enrichment of FFAT motifs in the 
Ascomycota, which was most notable amongst the Dothideomycetes class (Table S1). 
Although this is not a completely comprehensive analysis and predictions of FFAT motifs can 
be problematic due to the variability of the motif [49], our analysis does suggest that not all 
ACBD5 class proteins contain a strong FFAT motif. The reason for the presence of a FFAT 
motif in certain fungal species and not others is not clear.  
Atg37, ACBD4 as well as ACBD5 localize at peroxisomes, where they might perform 
complementary functions (see section 5.). However, ACBD4 isoforms lacking the TMD and 
protein interaction domains also exist [9] (Fig. 3). The FFAT motif is responsible for the 
function of ACBD4 and ACBD5 as ER tethering factors for peroxisomes by allowing 
interaction with ER VAP proteins (see section 5.). Since most fungal Atg37 proteins lack a 
FFAT motif, it is possible that Atg37 does not perform this function in the majority of fungi or 
it is replaced by a different interaction or tethering system [50].  
ACBD2/ECI2 is probably the most uniquely extended ACBD protein, as its ACBD domain is 
fused to a lipid metabolizing enzymatic Δ3,Δ2-enoyl-CoA isomerase domain (Fig. 3). ACBD2, 
which also localizes to peroxisomes, is a relatively late evolutionary invention and is only 
found in metazoans. Enzymatic activity measurements with recombinant wild type and mutant 
forms lacking the ACB domain showed that the ACB domain is not absolutely essential for the 
isomerase reaction but that the ACB domain may have a role in effectively channeling acyl-
CoAs to the isomerase domain [51]. At this time it cannot be excluded that the ACB domain 





Overall, the combination of protein interaction domains with ACB domains might reflect a 
property of extended ACBD proteins in channeling lipid substrate to proteins involved in lipid 
metabolism or membrane transport (Table 1). As mentioned earlier, the role of ACBDs in lipid 
metabolism and transport is poorly defined in biological systems, but controlling/modifying 
the activity of other proteins or tethering membranes together may be an additional important 
function. We speculate that the protein interaction motifs and TMDs have been evolved to link 
the ACB domain-containing proteins to specific subcellular membranes, where they are 
exploited for organelle-specific functions, e.g. in acquiring lipids required for metabolic 
pathways or membrane lipid transport (Table 1, 2; Fig. 4). The increasing complexity of 
subcellular compartments during evolution appears to have led to a comparable evolution in 
ACBD proteins. While animals and fungi appear to share a principle ACBD inventory 
(ACBD1-, ACBD6-, ACBD5-like forms), plants likely accomplished a rather independent 
evolutionary radiation into structurally distinct forms, which may fulfill comparable but also 
distinct cellular functions. 
This increasing functional complexity is reflected by the gain of diverse protein interaction 
domains in the extended ACBDs and the acquisition of functions, which could potentially be 
regulated by the acyl-CoA bound to the ACB [47,52] (or vice versa) or act independently (Fig. 
3). Protein extension can also potentially change the cellular location of the ACBD protein (e.g. 
ACBD4/5; see section 5.), regulate the function of binding partners via protein-protein 
interaction (e.g. ACBD3; see section 4.), or add a new activity (e.g. ACBD2; see section 3.). 
In the following sections of this review, we will discuss the current knowledge of the various 
functions of animal and fungal ACBDs. More information on the structure, localization and 
function of the plant ACBPs can be found in several recent reviews and will thus not be 
discussed in detail [2,53–56].  
 
2. ACBD1 and ACBD7 proteins 
ACBD1, originally known as acyl-CoA binding protein (ACBP) or diazepam-binding inhibitor 
(DBI), is the smallest member of the ACBD family, as it consists mainly of a soluble ACB 
domain (Fig. 3). This single-domain protein has been reported to bind saturated and unsaturated 
C14-C22 acyl-CoA esters with very high affinity and specificity [23,57,58], and has been 
associated with several lipid-related processes including the regulation of acyl-CoA transport 
to different acyl-CoA-utilizing enzymes [1] (Table 1, 2). ACBD1 is ubiquitously expressed 
[1,59], showing the highest expression in tissues with a significant fatty acid turnover such as 
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liver, testis and adipose tissue [60,61]. Additionally, ACBD1 is highly expressed in the brain, 
including the hypothalamus, where it was initially identified as neuropeptide and named DBI 
[62,63].  
Expression of ACBD1 can be activated by lipogenic as well as lipo-oxidative transcription 
factors, including sterol regulatory element-binding proteins (SREBPs), peroxisome 
proliferator-activated receptor α (PPARα) and PPARγ [64,65]. ACBD1 was suggested to 
function in a transcriptional feedback loop, since SREBPs and PPARγ were downregulated in 
ACBD1 overexpressing transgenic rats [66]. Additionally, ACBD1 could negatively affect 
PPAR activation, possibly by regulating the availability of PPAR-ligands, such as fatty acids, 
by its partly nuclear localization [67]. On the other hand, ACBD1 can enhance hepatocyte 
nuclear factor 4α (HNF-4α) transactivation suggesting an influence on the expression of HNF-
4α target genes, including genes involved in lipid transport and metabolism [68]. It has been 
shown that ACBD1 and HNF-4α co-localise within the nucleus and in the perinuclear region 
in rat hepatoma and COS-7 cells, and interact directly in vitro. This all emphasises the 
important function of ACBD1 in the regulation of lipid metabolism. Studies indicate the 
involvement of ACBD1 in acyl-CoA transport and pool formation, modulating acyl-CoA-
regulated enzymes, fatty acid synthesis and degradation, steroid and bile acid synthesis, and 
complex lipid synthesis (reviewed in [1,36,69]). Although ACBD1 function and peroxisome 
metabolism have not been linked directly, peroxisomes also contribute to several of these lipid-
related processes [11,70].  
ACBD1’s regulation by and participation in both lipogenic and lipo-oxidative pathways may 
reflect its function as an acyl-CoA carrier, protecting acyl-CoA esters from hydrolysis [71], 
and transporting acyl-CoA esters to compartments for lipid synthesis as well as degradation. 
Although ACBD1 is primarily a cytosolic protein, the protein also localises to specific 
compartments, including the ER, Golgi apparatus, mitochondria and nucleus [1,36] (Table 1, 
2; Fig. 4). In this respect, ligand-binding may be required for the interaction with distinct 
subcellular compartments as shown for the localization to the ER/Golgi [72]. ACBD1 is 
involved in the degradation of fatty acids by transporting and donating acyl-CoA esters to 
mitochondria, likely by binding to the outer mitochondrial membrane protein carnitine 
palmitoyltransferase I (CPTI), the rate limiting enzyme in mitochondrial β-oxidation of long-
chain fatty acids (LCFAs, C12-C20) [73–75]. Interestingly, ACBD1 has been reported to bind 
with high affinity to acyl-CoA esters with a chain length of 22 carbons [23], representing very 
long-chain fatty acids (VLCFAs, ≥C22). VLCFAs are not a substrate for CPTI and can only be 
oxidized in peroxisomes, not in mitochondria [11]. This leads to the possibility that ACBD1 
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may transport C22 acyl-CoA esters to peroxisomes for β-oxidation. A peroxisomal localisation 
of ACBD1 has not been reported, but interestingly in a genome-wide analysis in mouse 
ACBD1 mRNA was found to be localised to peroxisomes [76], which might suggest an 
alternative mechanism to control targeting of the protein, as has been suggested for several 
peroxisomal proteins in Saccharomyces cerevisiae [77]. Interestingly, an interaction between 
peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) and ACBD1 has been found in a high-
throughput yeast-two-hybrid screening of Drosophila melanogaster [78]. ACBD1 has also 
been associated with ACOX1 in a genome-wide transcript profiling study in which ACOX1 
gene expression was downregulated following ACBD1 knockdown in a human liver cancer 
cell line [79]. Thus, ACBD1 delivers LCFAs to mitochondria for degradation; whether ACBD1 
also localises to peroxisomes to deliver VLCFAs for degradation remains to be elucidated. 
Furthermore, ACBD1 may regulate the synthesis of VLCFAs. Depletion of the ACBD1 
orthologue in S. cerevisiae resulted in increased levels of C18:0 acyl-CoA esters and 
simultaneously in a strong reduction in C26:0 levels [80]. The study indicates that the transport 
of LCFAs to the chain elongation complex at the ER-membrane is impaired, so that these 
shorter-chain fatty acids cannot be elongated to VLCFAs. There is some evidence to suggest 
that ACBD1 may also play a role in the synthesis of VLCFAs in mammals. Increased C18:0-
CoA levels have been reported in the brain of ACBD1 deficient mice [63]. Since the oxidation 
of C18:0 was not altered and the expression of genes coding for de novo fatty acid synthesis 
enzymes, including ACC1 and FAS, were downregulated in ACBD1 depleted astrocytes, the 
increased levels of C18:0 may be the result of decreased LCFA elongation [63]. Another study 
found a decrease in the VLCFA content in the stratum corneum of ACBD1 deficient mice, 
although the elongation activity in the whole epidermis was not altered [81]. A role of ACBD1 
in the elongation of LCFAs has also been suggested in the synthesis of VLCFA ceramides. 
Both ceramide synthase 2 (CerS2) and CerS3 are activated by ligand-bound ACBD1 [82]. As 
both ceramide synthases utilize VLCFAs, it is likely that ACBD1 channels C22-C26-CoAs to 
CerS2 and CerS3. Gel shift assays show that ACBD1 has the ability to bind C24- and C26-
CoA, however, exact affinities have yet to be determined. As CerS2 interacts with both ACBD1 
[82] and VLCFA elongase ELOVL1 [83], the proteins may form a complex coordinating 
synthesis of VLCFA esters and ceramides. If ACBD1 does play a role in the synthesis of 
VLCFAs, it may indirectly affect the peroxisomal VLCFA β-oxidation. In addition, 
C24:0/C26:0-CoA has to be channelled from the ER to the peroxisomal membrane, but the 
proteins responsible for this remain unknown (see also section 5.). Therefore, ACBD1 might 
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be a candidate. Overall, ACBD1 plays important roles in the transport and donation of fatty 
acids for both degradation and synthesis. 
 
Besides its function as acyl-CoA carrier, ACBD1 was identified as a secreted brain 
neuropeptide, modulating the gamma-aminobutyric acid (GABA) type-A receptor, the main 
inhibitory neurotransmitter receptor located in brain synapses, and named diazepam-binding 
inhibitor (DBI), as it can inhibit the binding of the anxiolytic drug diazepam to the GABA 
receptor [84]. This could not be reproduced by others and a direct interaction between ACBD1 
and the GABA receptor has never been shown [23,85], but multiple studies support modulation 
of GABA transmission by ACBD1; ACBD1 and its proteolytic peptide fragments, including 
octadecaneuropeptide (ODN) produced by astroglial cells, regulate neuronal activities by 
stimulating neurosteroid biosynthesis [86] and neurogenesis [87] via GABA receptor 
modulation. ACBD1 can also act as a neuroprotective factor by activation of a metabotropic 
receptor [88]. Moreover, ACBD1 functions not only as synaptic neuropeptide (endozepine), 
but also influences brain physiology via its endogenous expression by regulating LCFA 
metabolism in astroglial cells [63]. Breitling (2004) [89] hypothesized that ACBD1 may 
contribute to the pathogenesis of peroxisomal disorders by dysregulating the GABAergic 
system, causing severe neurological defects. The author suggests that peroxisomal dysfunction 
leads to the accumulation of lipid metabolites e.g. acyl-CoA, causing downregulation of 
ACBD1 and hence in its function as a diazepam-binding inhibitor an over-activation in GABA 
signalling in neurons. However, the paper does not show a direct link between ACBD1 and 
peroxisomal disorders. The possible role of ACBD1 in the pathogenesis of peroxisomal 
disorders relies largely on the identification of ACBD1 in a microarray database search in 
which proteins were screened for three relative general criteria: its involvement in lipid 
metabolism, brain or neuronal function, and signalling or transcription [89], though the study 
proposes a different perspective on a possible ACBD1-peroxisome connection.  
Studies on rodent behaviour associate ACBD1 with social interest [90] and learning [91,92], 
and there are also links between ACBD1 and anxiety, since intracerebroventricular 
administration of ODN induces anxiogenic effects in rodents [93]. Additionally, ACBD1 
polymorphisms have been associated with anxiety disorders with panic attacks in humans [94]. 
However, anxiety-like behaviour was not affected in ACBD1 knock-out mice [95] as well as 
transgenic mice overexpressing ACBD1 [91]. It was recently reported that astroglial ACBD1 
deficiency promoted diet-induced obesity in mice [96]. This could be prevented by viral rescue 
of ACBD1 in astrocytes in the nucleus arcuatus (ARC), a hypothalamic nucleus that regulates 
15 
 
energy homeostasis. In line with this, it was very recently reported that short-term starvation 
of cultured cells or mice caused the autophagy-dependent secretion of ACBD1 [97]. In mice, 
injection of ACBD1 protein inhibited autophagy, induced lipogenesis, reduced glycemia, and 
stimulated appetite as well as weight gain. In contrast, ACBD1 neutralization enhanced 
autophagy, stimulated fatty acid oxidation, inhibited appetite, reduced weight gain in the 
context of a high-fat diet or leptin deficiency, and accelerated weight loss [97]. The ACBD1 
orthologues in S. cerevisiae and Caenorhabditis elegans have also been associated with food 
intake, indicating a conserved role for ACBD1 in appetite [98]. In humans, ACBD1 levels were 
observed to be abnormally low in persons with anorexia nervosa but excessively high in obese 
patients. Neutralization of ACBD1 might therefore constitute a strategy for treating obesity, 
whereas its administration may be beneficial in patients with anorexia [97]. Interestingly, 
ACBD1 paralog ACBD7 was also recently reported to influence feeding behaviour in mice 
[99]. ACBD7 and its processing product nonadecaneuropeptide (NDN) are produced by 
GABAergic and pro-opiomelanocortin (POMC) neuronal cells in the ARC. 
Intracerebroventricular administration of NDN inhibited food intake and enhanced energy 
expenditure in fasted mice. Both ACBD1 and ACBD7 seem to control feeding behaviour and 
energy expenditure via the melanocortin system [96,99] (Table 1). Peroxisomes have also been 
linked to this regulatory circuit; peroxisome proliferation-associated regulation of ROS levels 
in POMC neurons affected feeding behaviour in mice [100]. 
 
3. ACBD2/ECI2 protein 
ACBD2 (ECI2, PECI) is a peroxisomal Δ3,Δ2-enoyl-CoA isomerase, which represents a fusion 
of a larger C-terminal, enzymatic enoyl-CoA isomerase part to an N-terminal ACB domain, 
which is structurally similar to ACBD1 [51] (Fig. 3). The enzyme was first identified as an 
enoyl-CoA isomerase according to its sequence similarity to its yeast orthologue ECI1 and 
found to be localized to peroxisomes, in which it is imported into the organelle matrix, in 
human and mice [101,102] (Table 1, 2; Fig. 4). ACBD2’s ACB domain was identified 
according to its sequence similarity to ACBD1 [103]. A subsequent study on the rat enzyme 
further showed the bimodal distribution of ACBD2/ECI2 to peroxisomes as well as 
mitochondria [104], whilst its yeast homolog ECI2/DCI1 is solely peroxisomal [105,106]. 
Indeed, there are two cDNA isoforms in mammals; both exhibit a C-terminal peroxisomal 
targeting sequence 1 (PTS1), however, the longer form possesses an additional mitochondrial 
targeting sequence (MTS) at its N-terminus (aa 1-35). According to its enoyl-CoA isomerase 
domain, the protein is primarily required as an auxiliary enzyme for the β-oxidation of 
16 
 
unsaturated long- and VLCFAs, specifically to convert Δ3 into Δ2 enoyl-CoAs which can be 
further degraded by the straight-chain peroxisomal β-oxidation pathway [107] (Table 1). 
However, while the enzymatic function of the protein is well established, the role of its ACB 
domain remains unresolved. Supposedly, the ACB domain works as an acceptor for acyl-CoAs 
in the peroxisome matrix in order to efficiently exchange substrates or products with the 
protein’s enzymatic domain. In this regard, a recent study showed that a truncated version of 
ECI2 without the ACB domain was still functional but exhibited less enzymatic activity than 
the complete protein [51]. Interestingly, as described above, the ACB domain can only be found 
in animal species, whereas the homologous plant and fungal ECI2 proteins lack this N-terminal 
sequence extension. Moreover, in murine species a closely related peroxisomal protein, ECI3, 
has been described which also lacks the ACB domain found in ACBD2/ECI2 [108]. Thus, the 
ACB domain is not obligatory for ACBD2/ECI2’s enzymatic activity but may increase the 
effectivity of the enzymatic domain by channeling acyl-CoAs for their subsequent metabolism. 
Alternatively, the ACB domain of ACBD2 might fulfill an independent, hitherto undetected 
function for example as an intraorganellar acyl-CoA reservoir/transporter (Table 1). Recently, 
ACBD2/ECI2 was found to be significantly up-regulated in prostate cancer [109]. Further 
peroxisomal enzymes which are consistently induced in malignant prostate tumors are 
AMACR and ACOX3 [110,111], which both contribute to the catabolism of branched-chain 
fatty acids [112,113]. However, there seems to be no general up-regulation of peroxisomal lipid 
metabolism [111]. While ACBD2/ECI2’s role in the metabolism of unsaturated fatty acids does 
not explain such a concerted up-regulation with enzymes from the branched-chain fatty acid 
catabolism, these findings indicate that the protein’s ACB domain might contribute to other 
peroxisome pathways. 
A recent study reported that ACBD2/ECI2 might act as a tether between peroxisomes and 
mitochondria in mammalian cells [10] (Table 1, 2). As a mechanistic explanation the authors 
suggested that ACBD2/ECI2 interacts in parallel with the mitochondrial outer membrane 
import protein TOMM20 via its N-terminal MTS and with the cytosolic peroxisomal import 
receptor PEX5 via the C-terminal PTS1 sequence. Thereby, the protein would enter and block 
both import machineries and thus tether mitochondria and peroxisomes to each other [10]. 
Thus, in addition to ACBD4 and ACBD5 (see section 5.), ACBD2/ECI2 would be the third 
peroxisomal ACBD protein with an organelle tethering function, however, facilitating this 
function by a completely different and unique mechanism (see section 5. for comparison with 
ACBD4/5). Moreover, protein import into peroxisomes (folded protein) and mitochondria 
(unfolded sequence) differs substantially, adding further complexity to the formation of a 
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potential tethering complex. Remarkably, ACBD2/ECI2 is not the only protein with a 
combined N-terminal MTS and a C-terminal PTS1: several peroxisomal matrix proteins like 
e.g. peroxiredoxin 5, glutathione-S-transferase kappa or the Δ(3,5)-Δ(2,4)-dienoyl-CoA 
isomerase ECH1 are expressed as sequences or isoform sequences which have such opposing 
double-targeting signals (see [114]). Therefore, future studies are required to investigate if such 
proteins generally provide interactions between peroxisomes and mitochondria. Furthermore, 
it is indispensable to evaluate the existence of TOM20-ACBD2/ECI2-PEX5-PEX14 
multimeric complexes at the biochemical level and to provide triple staining, showing in 
parallel mitochondrial and peroxisomal markers and signals for ACBD2/ECI2 in order to verify 
that a significant proportion of the latter protein is localized directly at the contact sites between 
both organelles. 
 
4. ACBD3 protein 
ACBD3 was formerly named GCP60 (Golgi complex-associated protein of 60 kDa), Golgi 
complex-associated protein 1 (GOCAP1), PAP7 (cAMP-dependent protein kinase and 
peripheral-type benzodiazepine receptor associated protein 7) and GOLPH1 (Golgi 
phosphoprotein 1) [29]. The multiple names reflect the diverse functions of ACBD3 and its 
probably most prominent biophysical quality – the interaction with numerous, different 
proteins (Table 1, 2). ACBD3 consists of an N-terminal ACB domain followed by a charged 
amino acid region, a glutamine-rich coiled coil region (Q-domain) and a C-terminal GOLD 
domain (Fig. 3). Protein interactions are facilitated by binding to the Q-region but more 
frequently by the GOLD domain. Proteins with C-terminal GOLD domains regularly contain 
N-terminal lipid binding domains as found in ACBD3 and may function as double-headed 
adaptors connecting a protein and a lipid entity [43]. Thereby, these proteins may act as cargo 
loading proteins attaching soluble proteins to a specific membrane or by transmitting lipid 
species from the cytosol to a membrane-anchored interaction partner. 
 
According to its interaction with several members of the golgin-family, ACBD3’s GOLD 
domain appears to facilitate its localization to the Golgi compartment (Table 1, 2; Fig. 4). In 
this respect, ACBD3 is potentially part of a protein scaffold interacting with the golgins giantin 
[115] and golgin-45 [116] at either the Golgi rim or in between Golgi cisternae, respectively. 
In line with the differential localization of the golgin-45 and giantin interaction, ACBD3 
appears to participate in two distinct Golgi multiprotein complexes [117]. This scaffold-
forming quality of ACBD3 is supported by the finding that ACBD3 can self-interact via its 
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GOLD domain [118], assembling oligomers of high molecular weight [119]. This structure-
giving function of ACBD3 may be essential for maintaining Golgi integrity as ACBD3 
knockdown resulted in Golgi fragmentation [120]. Additionally, the protein’s GOLD domain 
is able to recruit further proteins to the Golgi membrane. ACBD3 was reported to localize the 
sphingolipid transfer protein FAPP2 to the Golgi, where it is required for transmitting 
glycosylceramides to the trans-Golgi compartment in order to be metabolized into complex 
glycosphingolipids [120]. Also associated with sphingolipid transport is ACBD3’s interaction 
with the ER-resident phosphatase PPM1L [18]. Two ACBD3 molecules were proposed to 
tether ER and Golgi membranes via parallel interaction with PPM1L and giantin. In 
cooperation with the ER-tethering protein VAPA, PPM1L can dephosphorylate and modulate 
the activity of the ceramide transport protein CERT at the contact site thereby regulating 
ceramide transport between the ER and Golgi [18].  
ACBD3 can further interact with Golgi proteins via its coiled-coil Q-region. Golgin-160 is a 
caspase-sensitive protein at the Golgi membrane, which after cleavage exposes a cryptic 
nuclear targeting signal inhibiting apoptosis upon nuclear translocation [121]. ACBD3 retains 
golgin-160 cleavage fragments at the Golgi surface, thereby preventing their nuclear 
translocation [122,123].  
Phosphatidylinositol 4-phosphate (PI4P) is an essential Golgi-enriched membrane lipid 
involved in cell signaling and membrane lipid transport [124]. Thus, for local PI4P synthesis, 
PI4 kinases (PI4K) have to localize at the Golgi. While type II PI4Ks are palmitoyl-anchored, 
type III PI4Ks like PI4KB are cytosolic and have to be recruited by interaction with membrane 
proteins. PI4KB is localized to the Golgi membrane via interaction with ACBD3’s Q-domain 
in parallel enhancing its catalytic activity [125]. The putative Rab33 GTPase-activating 
proteins (GAP) TBC1D22A and B were also reported to interact with ACBD3 via its Q-domain 
[118]. In this respect, facilitating multiple protein interactions via the protein’s different 
protein-binding domains (Q-domain for TBC1D22, GOLD-domain for golgin45) allows the 
formation of large protein oligomers like the ACBD3-GRASP55‐Golgin45-TBC1D22 
cisternal adhesion complex [116].  
In addition to the Golgi compartment, ACBD3 is localized at mitochondria where it interacts 
with the cholesterol translocator protein TSPO/peripheral benzodiazepine receptor (PBR) and 
the regulatory subunit RIα of protein kinase A (PKA) [126] (Table 1, 2; Fig. 4). TSPO is part 
of a multiprotein complex containing VDAC, StAR and ANT transmitting cholesterol to the 
inner mitochondrial membrane for steroid synthesis [127]. By interacting in concert with TSPO 
and RIα, ACBD3 functions as an A kinase anchoring protein (AKAP) connecting the PKA 
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holoenzyme with its target TSPO to regulate steroidogenesis [126,128]. Interestingly, ACBD1 
was also reported to interact with TSPO to stimulate steroidogenesis [129,130], which may 
suggest that both ACBDs contribute to a shared protein network regulating mitochondrial 
cholesterol transport. 
ACBD3 is also observed at the plasma membrane in intestinal and neuronal cells [131,132] 
(Table 1). In neurons, ACBD3 interconnects the iron transporter DMT1 (divalent metal 
transporter 1) with the NO-activated GTPase DEXRAS1, thereby enabling regulation of 
cellular iron uptake [131]. In the intestine, ACBD3 interaction with DMT1 was found to 
depend on the cellular metabolic state. Under iron starvation conditions, DMT1 and ACBD3 
both localized to the apical brush border membrane [132]. In response to iron feeding, the 
proteins translocated to different subcellular sites (for ACBD3 the basolateral membrane and 
Golgi). Thus, ACBD3-binding to DMT1 might contribute to the regulation of DMT1 
internalization thereby influencing iron influx [132]. 
In addition to its membrane associated functions, ACBD3 is able to act in the cytosol. During 
division of neuronal progenitors, the cytosolic cell fate determining protein Numb is 
asymmetrically distributed among daughter cells inducing specification into a neuron and 
another progenitor cell for self-renewal [133]. During mitosis-induced Golgi fragmentation, 
ACBD3 is released into the cytosol where it interacts with Numb’s N-terminal region 
[134,135]. Numb’s N-terminal amino acid sequence exhibits two phosphorylation sites 
targeted by the atypical Protein Kinase C (aPKC) in the process of asymmetric Numb 
segregation. Thus, ACBD3 might modulate accessibility of these phosphorylation sites thereby 
regulating asymmetric Numb distribution into daughter cells. 
 
Besides its cellular functions, ACBD3 has been co-opted for the replication of multiple 
members of the picornavirus family, which include important human pathogens such as 
poliovirus, enterovirus 71, coxsackieviruses, hepatitis A virus and rhinoviruses. PI4KB is an 
essential host factor for the formation of so-called replication organelles (RO) – rearranged 
membrane structures required for viral genome replication [22]. At the RO membrane, PI4KB 
synthesizes PI4P thereby attracting PI4P-binding proteins to the RO to be exploited for the 
viral RNA replication machinery [136]. In order to recruit PI4KB to the RO, ACBD3 
interconnects the viral 2B, 2BC, 2C, 3A and 3B protein complex with PI4KB [137,138]. Since 
the viral 3A protein competes with golgins in binding to ACBD3’s GOLD domain, the 
ACBD3-3A interaction likely induces a release of ACBD3 from the Golgi, thus ‘piggybacking’ 
PI4KB to the RO [118,139]. As reported above, ACBD3 not only binds PI4KB but also 
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amplifies its enzymatic activity, thus increasing PI4P synthesis at RO membrane [125]. 
Remarkably, ACBD3 has been recently reported to connect the ER-Golgi cholesterol transport 
machinery with the RO of the Aichi virus [140]. The viral 2B, 2BC, 2C, 3A, and 3AB protein 
complex was found to interact with the cholesterol transferring oxysterol-binding protein 
(OSBP) thereby assembling a VAP/OSBP/SAC1 complex at RO-ER membrane contact sites. 
In this context, ACBD3 is recruited to the RO via interaction with each of the viral proteins. A 
parallel additional interaction with the VAPA/B, SAC1 and OSBP complex stabilizes the 
complex between the ER proteins VAP/OSBP/SAC1 and the viral RO proteins in order to 
interconnect the host ER membrane with the viral RO for cholesterol transfer from the ER to 
the RO. 
 
Despite the increasing number of identified protein interactions implying that ACBD3 is a 
central player in cellular signaling and membrane domain organization [29,117], current 
knowledge on the relevance of ACBD3’s name giving ACB domain is surprisingly scarce. Its 
predicted 3D-structure exhibits an altered structural conformation compared to the 
experimentally deduced 3D-structures of the ACB domains from ACBD1, ACBD2 and 
ACBD6, thus implying that ACBD3 binds distinct acyl-CoA species [29]. Moreover, 
incubation of purified ACBD3 with either palmitoyl- or oleoyl-CoA resulted in the formation 
of protein oligomers suggesting that the protein changes its conformation upon acyl-CoA 
binding [119]. This may indicate that ACBD3 function is regulated by acyl-CoA binding. 
SREBP1 is a nuclear transcription factor activating de novo synthesis of fatty acids [141]. 
ACBD3 expression was recently shown to attenuate nuclear translocation of SREBP1 by 
interacting and stabilizing SREBP1’s membrane-associated full-length form at the Golgi 
thereby reducing cellular palmitate synthesis [52]. Expression of ACBD3 lacking the ACB 
domain did not induce this effect. Thus, ACBD3 might sense intracellular acyl-CoA 
availability with its ACB domain, which induces changes in ACBD3 conformation stabilizing 
interaction and Golgi association of full-length SREBP1. In this regard, ACBD3 may help to 
decrease gene expression of fatty acid synthesizing proteins when intracellular acyl-CoA pools 
are high. However, the actual binding affinities of ACBD3 for distinct acyl-CoAs have still to 
be determined in order to understand its particular role in the cellular network regulating lipid 
homeostasis. 
As illustrated in this section, ACBD3 appears to be a multivalent scaffolding protein, regulating 
interactions between several core protein complexes and some more dynamically or 
temporarily associated functional proteins. Most of the interactions appear to be confined to 
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the Golgi, where ACBD3 appears to localize by interaction with different member of the 
golgin-family in order to recruit further proteins to the Golgi-membrane. Nevertheless, the 
function of the bipartite protein interaction domains of ACBD3 can also be exploited at other 
subcellular membranes like the mitochondrial outer or plasma membrane. Several of the 
functions fulfilled by ACBD3 might be independent of the protein’s ACB domain, while others 
might link the cell’s lipid metabolic status with the general cellular homeostasis. In this respect, 
it remains unclear if the ACB domain was fused to a precursor protein with an already complex 
interactome, or if novel acyl-CoA binding independent functions were acquired after fusion to 
its C-terminal extension by a stepwise diversification protein interaction network. In order to 
understand ACBD3s role in cellular physiology, it will be important to unravel how ACBD3 
can coordinate its large, variable and dynamic protein interaction network, and to identify 
potential targets for posttranslational modifications, which could facilitate the underlying 
regulatory mechanisms. 
 
5. ACBD4/5 and Atg37 proteins 
ACBD4 and ACBD5 proteins are only found in animals and fungi (Fig 1, Fig. S1). The 
transcript variants encoding a C-terminal TMD have recently been found to localise to 
peroxisomes [7] (Table 1, 2; Fig. 4). The autophagy related protein Atg37 is the homologue 
of ACBD4/5 in fungi and likewise an ACB domain protein at the peroxisomal membrane. In 
the yeast Pichia pastoris, Atg37 is required for the formation of phagophores (membrane 
precursors formed upon induction of autophagy) during pexophagy, the specific degradation 
of peroxisomes [47,142]. The role of Atg37 in pexophagy is in the recruitment of the 
pexophagic receptor complexes which link peroxisomes to the autophagic machinery. Atg37 
interacts with the pexophagy-specific autophagy receptor Atg30, allowing recruitment of 
peroxisomes to the pexophagic complex, and facilitating efficient degradation of peroxisomes 
[142]. Interestingly the interaction between Atg37 and Atg30 requires the ACB domain of 
Atg37, and in vitro Atg30 and palmitoyl-CoA compete for Atg37 binding, suggesting a 
potential mechanism for how Atg37-mediated pexophagy could be regulated [47]. Mammalian 
ACBD5s and isoform 2 of ACBD4 are C-tail-anchored peroxisomal membrane proteins with 
an N-terminal ACB domain [7,47,143,144] (Fig. 3). It was recently revealed that ACBD5 and 
ACBD4 function as molecular tethers in the formation of peroxisome-ER membrane contact 
sites (MCSs) [4,5,9] (Table 1, 2; Fig. 4). An estimated 80-90% of peroxisomes are closely 
associated with the ER, suggesting an important physiological role of those contacts in 
mammalian cells [145]. Both ACBD5 and ACBD4 interact through a FFAT-like motif with 
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VAP proteins (VAPA, VAPB) at the ER [4,5,9]. VAP proteins (vesicle-associated membrane 
protein (VAMP)–associated proteins) are C-tail-anchored adaptor proteins in the ER 
membrane with roles in inter-organellar lipid exchange, MCS formation, and membrane 
trafficking [146]. They possess a major sperm protein (MSP) domain that interacts with the 
FFAT(-like) motif of protein partners located on the opposing membrane [147]. Supporting a 
function in peroxisome-ER tethering, co-expression of ACBD5 and VAPB increased contact 
sites, whereas depletion reduced them. Whereas mutations in the ACBD4/5 FFAT-like motif 
abolished interaction with VAPB and reduced peroxisome-ER interaction, a functional N-
terminal ACB domain was not required for the tethering function [4,5,9]. In our analysis of the 
FFAT motif of ACBD4/5 proteins across species (see section 1.) we could not detect a specific 
FFAT motif in Pichia pastoris Atg37 suggesting that, unlike ACBD4/5, it may not have ER 
tethering function. Conversely, ACBD4/5 may not have a function in pexophagy [6,8].  
Disruption of the ACBD5-VAP contacts increased peroxisome motility, revealing a new role 
of peroxisome-ER tethering in the regulation of peroxisome mobility and positioning [4,5] 
(Table 1). Loss of peroxisome-ER contacts also prevented peroxisomal membrane expansion, 
which is required for the formation of peroxisomes by membrane growth and division [4,148]. 
Conversely, overexpression of ACBD5 in cells deficient in peroxisome fission induced 
peroxisome elongation [5]. These observations support a role of the ACBD5-VAP contact in 
peroxisome biogenesis and membrane lipid transfer. Many of the metabolic functions of 
peroxisomes in lipid metabolism are carried out in partnership with the ER [14]. This includes 
the synthesis of ether-phospholipids (e.g. myelin sheath lipids), which in mammalian cells is 
initiated in peroxisomes but completed in the ER. The first patients diagnosed with a functional 
ACBD5 deficiency presented with retinal dystrophy and white matter disease [149]. Further 
characterisation revealed a peroxisome-based disorder with progressive leukodystrophy, 
ataxia, progressive microcephaly with facial dysmorphisms, in addition to retinal dystrophy 
[6,8]. Patients showed a loss of ACBD5 protein, a reduction in ether-phospholipids [150], and 
accumulation of VLCFAs due to a dysfunction in peroxisomal β-oxidation [6,8]. It is suggested 
that ACBD5 facilitates transport of VLCFAs into peroxisomes for subsequent β-oxidation 
[6,8,150]. We hypothesize that the ACBD5-VAP tether contributes to the formation of a 
peroxisome-ER metabolic hub that allows control of fatty acid chain length: Fatty acids 
elongated at the ER can be prevented from synthetizing excess amounts of over-long VLCFA 
via transmission to peroxisomes for immediate degradation via β-oxidation [17]. In this context 
it should be noted that a disruption of peroxisome metabolism not only prevents VLCFA 
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degradation but induces fatty acid elongation at the ER [151] suggesting that fatty acid 
synthesis and break down are regulated in a tightly controlled feed-back mechanism, 
potentially via coordinating catabolic and anabolic pathways at peroxisome-ER contact sites. 
Remarkably, the long-chain acyl-CoA synthetase ACSL1 was identified as a direct interaction 
partner of ACBD5 and VAPB [152]. As outlined above, there is evidence that inter-organelle 
communication at peroxisome-ER contacts mediated by the ACBD5-VAP tether regulates 
several physiological processes including fatty acid/lipid metabolism, membrane lipid 
exchange, peroxisome biogenesis, mobility and positioning [17] (Table 1, 2). 
Interestingly, a recent interactomics study uncovered an important role for peroxisomes in Zika 
virus infection and revealed the peroxisome-ER tether proteins ACBD5 and VAPA/B as host 
interaction proteins [21]. The study used BioID and IP-MS to generate a global Zika virus-host 
protein interactome for the ten polypeptides encoded in the viral genome. Extensive organellar 
targeting of Zika virus to host cell organelles involved in lipid biosynthesis and metabolism, 
including the ER, peroxisome and lipid droplets was uncovered [21]. The non-structural viral 
protein NS2A specifically targeted peroxisomal membranes, and Zika virus replication was 
significantly impaired in cells lacking functional peroxisomes. The authors propose that NS2A 
targets peroxisomes to remodel host-cell lipid populations and/or to effect viral escape from 
the host innate immune response, which was previously shown for Dengue and West Nile virus 
[153]. Those viruses can cause mosquito-borne neurological disease and death. Lipidomic 
analysis revealed increased levels of plasmalogens in serum of Zika virus-infected subjects 
further suggesting a link between viral life cycle and peroxisomes, which are required for 
plasmalogen biosynthesis [154].  
 
There is firm evidence now that ACBD4/5 mediate tethering of peroxisomes to the ER and 
contribute to fatty acid/lipid metabolism at the peroxisome-ER interface. It remains to be 
established how fatty acids/lipids are exchanged between peroxisomes and ER at those 
contacts, and how these mechanisms impact on human health and disease.  
 
6. ACBD6 proteins 
ACBD proteins carrying ankyrin-repeat motifs represent the second most abundant ACBD 
forms predicted from eukaryotic genomes [1]. The representative member of the mammalian 
family is annotated as ACBD6 (Fig. 3). It was first identified in hematopoietic cells [155], but 
is produced in other tissues and cells [156,157]. The human ACBD6 is a soluble protein 
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detected in the cytosol and nuclei of cells [155] and is involved in the regulation of acylation 
of lipids and proteins [19,119,158,159] (Table 1). ACBD6 supports the re-acylation of 
lysophospholipids, which is an essential reaction necessary for the repair/renewal of damaged 
lipids in membranes. ACBD6 controls the rate of acylation of lipids at the level of acyl-
CoA:lysophospholipid acyltransferases (LPLATs), preventing the inhibition of the LPLAT by 
excess acyl-CoAs. Acyl-CoAs have detergent-like properties that can damage proteins and the 
acyl-CoA sequestration by ACBD6 appears to protect the enzymes by limiting availability of 
free acyl-CoAs [119]. Interestingly, the acylation supporting function of ACBD6 can be 
exploited by pathogens. In cells infected with the bacterium Chlamydia trachomatis, ACBD6 
was found to be recruited into the parasitophorous vacuole and depleted from the host 
compartment [19,160]. Moreover, ACBD6 modulates the bacterial acylating enzymes and may 
support remodeling of host lipids with bacterial-derived branched-chain fatty acids in pathogen 
infected cells [19,119,161]. Interestingly, peroxisomes are also translocated to the 
parasitophorous vacuole and may be exploited to produce bacteria-specific plasmalogens 
[162]. 
The N-myristoylation of proteins can affect their activity and association with membranes, and 
mediates oligomeric assembly and the interaction with other proteins [163,164]. After the 
removal of the initiator methionine, N-myristoyltransferases (NMTs) catalyze the amide 
linkage of the rare 14-carbon long saturated chain of myristoyl-CoA to an N-terminal glycine 
of proteins [163,165–167]. They are essential for the maintenance of cellular functions but as 
well for the intracellular development of pathogens such as parasitic protozoa, fungi, and 
viruses [168–172]. In this pathway, human ACBD6 stimulates the activity of the N-
myristoyltransferases NMT1/NMT2 and provides specificity for their substrate [158,159] 
(Table 1, 2; Fig. 4). N-myristoyltransferases lack binding specificity for the 14-carbon acyl 
chain and other acyl-CoAs, such as the more abundant C16-CoA, can bind and block the 
enzymes [163,173,174]. ACBD6 interacts with NMT2 and forms a complex via its C-terminal 
domain, in which the ankyrin-repeat motifs are located [159]. Likewise, the Drosophila 
ACBD6 homolog Anox interacts with the NMT enzyme and may indicate that a similar 
mechanism is conserved in the fruit fly [175,176]. In the complex, ACBD6 stimulates activity 
and favors binding of C14-CoA to NMT2 even in the presence of competing acyl-CoAs. 
Complex formation does not require the ACB domain but the stimulatory effect of ACBD6 is 
dependent on both the presence of the ankyrin-repeat region and of an intact ACB domain. 
Acyl-CoA-bound ACBD6 forms a more stimulatory complex than apoACBD6, and ACB 
mutants deficient in ligand binding are impaired in their ability to stimulate NMT activity 
25 
 
[158,159]. Phosphorylation of ACBD6 enhances the N-myristoyltransferase activity [158]. The 
regulation of N-myristoyltransferase is even conserved in the apicomplexan parasite 
Plasmodium falciparum ACBD6-like protein. This enzyme is more sensitive to competition by 
C12-CoA rather than C16-CoA and both P. falciparum and human ACBD6 protein can provide 
protection against C12-CoA [158].  
Additionally, ACBD6 may be involved in the control of cellular metabolism at different 
regulatory levels as suggested by findings from invertebrate homologs. The loss of the 
Drosophila ACBD6 Anox in a mutant fly resulted in a significant decrease in feeding activity 
and food intake [175]. Anox is expressed in chemosensory organs and neurons of the central 
nervous system and appears essential for the regulation of insulin signaling by modulating 
sugar-induced nerve responses. In this respect, it should be mentioned that lipid and glucose-
sensitive neurons of the CNS appear to form complex regulatory networks required for 
maintaining energy and glucose homeostasis [177], which might partially explain the 
association of an acyl-CoA binding protein with insulin signaling pathways in the fruit fly. The 
absence of the Caenorhabditis elegans ACBD6 homolog CeACBP-5 led to a 50% increase in 
the production of lipid droplets [178]. In the nematode, acyl-CoA binding proteins appear to 
regulate triacylglycerol metabolism, which was also drastically affected by loss of CeACBP-
1.  
Remarkably, acyl-CoA binding in ACBD6 appears to be regulated by phosphorylation. While 
several ACBD members are phosphorylated in vivo, ACBD6 appears to be the only member 
that is phosphorylated on residues within the ACB domain [158,179,180]. The two ACBD6 
residues known to be phosphorylated are serine 106 (Ser106) and Ser108 which are -1 and +1 
residue of the fourth α–helix of the ACB domain of human ACBD6 (according to the structural 
information available at entry PDB:2COP of ProteinDataBase). These serine residues are not 
essential for acyl-CoA binding and for the localization of ACBD6 [158]. Ser106 is conserved 
in the ACB domain of some other ACBD proteins but it is not known to be phosphorylated in 
these forms and the first residue of α-helix 4 (Ser108 in ACBD6) is often replaced by a 
glutamate residue. Purified phospho-ACBD6 protein has higher acyl-CoA binding capacity 
than ACBD6 and displacement of bound acyl-CoA to phospho-ACBD6 required a higher 
concentration of competitors compared to the non-phosphorylated form [158]. Glutamate can 
often mimic phosphorylation of a serine residue due to its negative charge, and the ‘permanent’ 
phosphorylation of the +1 residue of α–helix 4 compared to an alternative phospho-state of 
Ser108 supports the notion that acyl-CoA binding activity of ACBD6 can be regulated in vivo. 
Cell cycle global profiling of human phospho-proteins detected a specific upregulation of 
26 
 
phosphorylation of ACBD6 Ser106 and Ser108 during the M-phase [179,180]. This finding 
strongly suggests that function of the phosphorylated form of ACBD6 is increased during 
mitosis and also raise the question whether de-phosphorylation is regulated.  
Ankyrin-repeat containing ACBDs are not restricted to metazoans but are found among all 
three organismal phyla and were initially identified in Arabidopsis thaliana [154,155]. Of note, 
a general difference between the ACBP class II found in plants and the ACBD6 forms of 
metazoans, fungi and amoebozoa is the presence of a potential N-terminal TMD or 
hydrophobic signaling sequence (Fig. 3). In line with this motif, the two plant homologs 
AtACBP1 and AtACBP2 are located in the ER and plasma membrane but it remains to be 
determined if the N-terminal sequence functions as a true membrane anchor [57,156,157]. 
AtACBP1 and AtACBP2 are essential for embryonic development and absence of ACBP1 
alters adaptation to cold and drought, heavy-metal stresses, sterol and very-long acyl-CoA 
metabolism and abscisic acid signaling [58,158–163]. AtACBP2 interacts with the ethylene-
responsive element-binding protein AtEBP via its ankyrin-repeat motifs [157]. AtACBP1 
protein has been shown to interact with a broad variety of compounds, such as lead [161], the 
phospholipids phosphatidylcholine and phosphatidic acid [159,160], and the phospholipase 
PLDα [159]. Moreover, ACBP class II proteins play a role in pathogen infection and growth. 
The absence of ACBP1 increases susceptibility of leaves to infection by the fungal pathogen 
Botrytis cinerea as a result of a decreased wax production and weakened cuticle layer [163]. 
Orthologous ankyrin-containing proteins from apicomplexan parasites (alveolata) are also 
membrane bound, but their N-terminal structure is heterogeneous. Cryptosporidium parvum 
CpACBP1 is associated to the parasitophorous vacuolar membrane but does not contain a 
potential TMD sequence [164,165]. Plasmodium falciparum, Plasmodium vivax and 
Toxoplasma gondii possess ACBD6-like proteins which exhibit predicted transmembrane 
motifs at their N-terminal end [164,166] and are thus potentially membrane-anchored. 
Toxoplasma gondii TgACBP2 is localized in the mitochondrial membrane but the 
phosphorylated form is sorted to the plasma membrane [167]. The acyl-CoA binding activity 
of the protozoan Cryptosporidium parvum, CpACBP1 and of Plasmodium falciparum 
PfACBD6 have been determined and show highest affinities for a chain length between 14-16 
C-atoms [164,165]. Toxoplasma gondii TgACBP2 is important for cardiolipin metabolism and 
intracellular growth of the parasite [167], while the function of the homologs from 
Cryptosporidium and Plasmodium is still unknown. As exemplified in the last paragraph, 
evolutionary radiation can significantly modulate the protein architecture of ACBD 
orthologues in different organism groups. In this respect, the proteins may combine functions 
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which are still conserved among species with novel ones which were e.g. acquired by gaining 
access to alternative subcellular localizations with different surrounding protein environments.  
The functional relevance of mutations in the ACBD6 gene, which have not been associated 
with a disease so far, is now under investigation. Homozygous loss-of-function mutations in 
ACBD6 have been identified in individuals with a neurodevelopmental disorder (ES&FK, 
personal communication). Analysis of the processes regulated by ACBD6 (protein and lipid 
acylation) affecting the activities of neuronal proteins by lipid-modification represents a new 
avenue of research in neuron biology. 
 
7. Concluding remarks 
There is compelling evidence now that ACBD proteins are ancient proteins which have evolved 
to fulfil other functions in addition to their original roles in acyl-CoA transport and 
stabilisation. The small soluble ACBDs appear to act as acyl-CoA transporters and reservoirs, 
enabling efficient provision and targeting of acyl-CoA to lipid metabolizing subcellular 
compartments. However, extended ACBDs have evolved which combine ACB domains with 
a membrane anchor, enzymatic activity or protein interaction domains. An increase in the 
complexity of ACBDs may have been driven by the evolution of more complex subcellular 
compartments. This has led to the acquisition of additional functions, which are no longer 
directly linked to the original acyl-CoA binding function. It also allowed ACB domain-
containing proteins to be linked to specific subcellular membranes, where they developed 
organelle-specific functions in acquiring lipids for metabolic pathways, membrane lipid 
trafficking or signalling. Several ACBDs have been linked to peroxisome function and act as 
tethers or scaffold proteins at membrane contact sites. The medical importance of ACBDs is 
also increasingly recognised, as several are targeted by different pathogens to exploit cellular 
lipid metabolism. ACBD5 deficiency has recently been described as a new peroxisomal 
disorder characterised by the accumulation of VLCFA and neurological abnormalities (see 
section 5.). It will now be important to identify and characterise further interaction partners of 
ACBDs at organelle membranes, to understand how protein scaffolds at membranes are 
formed, and how their formation and ACBD interaction is regulated. Posttranslational 
modifications such as phosphorylation likely play a role. A challenge will be to investigate if 
and how acyl-CoA binding regulates protein interactions, and how this may be influenced by 
interaction of the ACB domain with different substrates. Further understanding of the 
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molecular mechanisms and function of ACBDs may lead to therapeutic approaches to combat 
pathogens and impact on our understanding of human disease. 
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Table 1 Cellular localisation and proposed functions of mammalian ACBDs 
Table 2 Association of ACBDs* in protein complexes (findings from high-throughput 
approaches not included) 
 
Figure 1 Evolution of Acyl-CoA binding domain containing proteins (ACBDs) among 
metazoans. The scheme summarizes data from a phylogenetic reconstruction including 449 
sequences from animals, fungi and plants (for details see Fig. S1). After alignment by the 
ClustalW 2.0 algorithm included in the Seaview software package and manual correction of 
misaligned sequences, phylogenetic reconstructions were performed with PhyML3.0 using the 
aLRT algorithm for branch support, BioNJ for tree topology optimization, 4 rate categories for 
RHAS (Rate Heterogeneity Among Sites) modelling and including NNI and SPR tree 
searching operations. Furthermore, we used Marcoil1.0 online prediction tool [181] to screen 
the sequences for coiled-coil motifs and TMHMM2.0 and TMPred for TMD prediction 
[182,183]. Colours highlight four major categories of ACBDs – the C-terminally membrane-
anchored ACBD4/5 (green), the enoyl-CoA isomerase containing ACBD2 (blue), the small 
soluble ACBD1 (red) and the extended forms with protein interaction domains ACBD3/6 and 
extended plant forms (purple; ACBP class II-IV). Taxonomic categories shown name the 
minimum organism group in which a distinct protein subfamily was detected. E.g. while 
ACBD2 was only found in vertebrate and invertebrate animals, ACBD4/5 occur in both 
animals and fungi, more specifically in basidiomycota and several early branching fungal 
divisions of incertae sedis (*symbolized with Mucoromycota in the Figure). By contrast, the 
ankyrin repeat-containing ACBD6/ACBP II is distributed among all metazoans indicating its 
early evolution from the ACBD1 form. 
 
Figure 2 3D predictions of selected acyl-CoA binding proteins/domains. The predictions were 
accomplished with Phyre2 using entire cDNA sequences from ACBD1 of Homo sapiens (F) 
and homologous small ACBDs from the β-proteobacterium Aquabacterium parvum beta (A), 
an hitherto undefined ACBD sequence (TFG05618) of Lokiarchaeota origin (B), the 
choanoflagellate Monosiga brevicollis, the Mucoromycota fungus Rhizopus oryzae (C), the 
moss Sphagnum fallax (D); for comparison the ACB domain of human ACBD5 was added 
subjected to 3D prediction (G). Hydrophobic regions in the protein surface structure are 
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highlighted in red and residues conserved among all species are shown. (H) Tertiary structure 
reconstructions from (A) – (F) are additionally shown as sequence overlay in ribbon cartoon 
format to illustrate the significant structural homology in the distantly related species (depicted 
in different colours). Conversion of the PDB files into graphical illustrations was performed 
with PyMOL 2.3.2. 
 
Figure 3 Domain structures of animal, fungal and plant acyl-CoA binding proteins. The 
schemes represent ACBDs from Homo sapiens (Mammalia, Animalia), Ustilago maydis 
(Basidiomycota, Fungi) and Oryza sativa (Angiospermae, Planta); sequence and domain 
lengths as well as position are proportional to the original protein structure. For some ACBDs, 
several isoforms have been reported or predicted. In such cases, only the currently best 
characterized isoform is presented. Note the structural similarity between the mammalian, 
fungal and plant ankyrin repeat-containing ACBDs, which suggests an early evolution already 
found in the LECA. ECH, enoyl-CoA hydratase domain; FFAT, two phenylalanines in an 
acidic tract motif 
 
Figure 4 Schematic overview of the localisation of ACBD proteins.  
ACBD, acyl-CoA binding domain containing protein (ACBD1-8); ER, endoplasmic reticulum; 
LPLAT, acyl-CoA:lysophospholipid acyltransferase; NMT2, N-myristoyltransferase 2; PO, 
peroxisome; TSPO, translocator protein for cholesterol; VAPB, vesicle-associated membrane 
protein (VAMP)–associated protein B. For details see sections 2-6 as well as Tables 1 and 2. 
 
Supplementary Table S1 Analysis of FFAT motifs. In the initial analysis 56 fungal and 37 
animal (20 vertebrate and 17 invertebrate) ACBD5 protein sequences were analysed for FFAT 
motifs using a previously described position weighted matrix analysis [48]. This gives a FFAT 
“score” based on the number of suboptimal elements within the motif with a cut-off of ≤2.5. 
This analysis was then expanded to include further fungal species to look for enrichment in a 
particular Order/Class. To confirm significance for the Animal, Fungal and Asmoycota 
sequences a randomisation analysis was performed in which amino acid sequences were 
randomised 10 times and the FFAT analysis repeated to give a false positive discovery or 
background rate. For each strength of FFAT score (≤1.0, ≤1.5, ≤2.0, ≤2.5), the observed 
number of motifs was compared with the background discovery rates across all amino acid 




Supplementary Figure S1 Cladogram for ACBD containing sequences found in animals, 
fungi and plants (animal branches in red, plant branches in green, fungal branches in blue). The 
sequences were derived from Genbank and JGI and cover the major metazoan branches; the 
cladogram was constructed with PHYML 3.0 contained in the Seaview software package. 
Circular cladograms were drawn with Mesquite v3.2. Numbers at the branch nodes represent 
branching probabilities. *several sequences from other early branching fungal groups are 
included in the Mucoromycota section. 
 
Supplementary Figure S2 Evolution of the 3 small, soluble ACBDs found in mammals. The 
sequences were derived from Genbank and cover all major vertebrate and invertebrate classes; 
ACBD2 sequences branching next to ACBD1 in Fig. S1 were used as outgroup. The cladogram 
was constructed with PHYML 3.0 contained in the Seaview software package. Circular 
cladograms were drawn with Mesquite v3.2. As shown, all vertebrates possess two small 
soluble forms – ACBD1 and ACBD7. In addition, a second gene duplication resulted in another 
form – ACBD8 – found in mammals including marsupials. Interestingly, similar sequences 
were found in the Archosauria and Testudines indicating that ACBD8 may have been 
originated already during reptilian evolution. However, more reptilian sequences are required 
to more reliably reconstruct the evolutionary relation of these sequences. Numbers at the 
branch nodes represent branching probabilities. i.s., incertae sedis; vert., vertebrata; invert., 
invertebrata.  
 
Supplementary Figure S3 Alignment of selected small ACBD proteins from animals, plants, 
fungi, choanoflagellates, eubacteria and archaea. Conserved residues are indicated by asterisks, 
neutral amino acid substitutions by colons/points. Note that the major amino acid residues 
involved in acyl-CoA binding (Lys33, Lys55, Tyr29, Tyr32, Tyr74, Phe6, Leu26, [36]) are 
conserved in all species. Alignment was performed with ClustalW 2.1 [184]. 
 
Supplementary Figure S4 Phylogenetic analysis of small ACBD forms found in prokaryotes. 
The sequences were derived from Genbank and contain sequences from the major prokaryote 
and eukaryote organism groups. Archaeal sequences are derived from metagenome sequencing 
data. Circular cladograms were drawn with Mesquite v3.2. Vertebrate ACBD2 sequences as 
depicted in Fig. S1 were used as the outgroup. The cladogram was constructed with PHYML 
3.0 contained in the Seaview software package. Note that the small ACBP-like sequences 
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identified in β-, γ-, δ-proteobacteria, bacteroidetes and archaea cluster in distinct branches next 
to the eukaryotic ACBDs implying an evolution from a shared early ancestor protein. In 
contrast, the few sequences found in α-proteobacteria (α) and actinobacteria (Ac) align with 
sequences from different branches, suggesting that they might have arisen by lateral gene 
transfer or result from contaminated DNA. Numbers at the branch nodes represent branching 
probabilities. *several sequences from other early branching fungal groups are included in the 
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For details see sections 2-6 and Fig. 4. Note that isoforms are not included. ER, endoplasmic 
reticulum; PO, peroxisome 






Table 2: Association of ACBDs* in protein complexes (findings from high-throughput 
approaches not included) 
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Rhizopus_oryzae              -------MPSQQFTTAAEEVQK--LSTKPSNDELLELYGLFKQATVGDNETSK 
Sphagnum_fallax              ------MGLKEDFDQAAKDALT--LPESTTNEDKLILYGLFKVATVGKPETSR 
Homo_sapiens                 ----MEMDLKEEFEKASETVMN--LSERPSNEELLKLYSFYKQGTEGDVSGKR 
Aquabacterium_parvum_beta    -----MSDLQAQFEKALADSKL--LPAKPDNNTLLKIYSLFKQGSVGDVQGDR 
Lokiarchaeota_archaeon       MSVDNGKTLKSEFEEAIARSDK--LPKQP-VDTQLELYGLYKQALFGDVTGER 
Monosiga_brevicollis         -------MTEAQFNKAVWLIRNGPAVGDSSNETKLSFYKYYKQATVGDNNESQ 
                                      . :*  *            .  :  * :*  :* .  *.   .: 
                                 ---HHHHHHHHHHHHHHH--------HHHHHHHHHHHHHH--------- 
 
 
Rhizopus_oryzae              P-TFDIKGRYKWDAWTKLKGMSQEEAEQKYIELVEKLKASQ----------- 
Sphagnum_fallax              PGIFDPKGRAKWDAWKKVEDKSKDEAMQEYIVKVTQLKEA------------ 
Homo_sapiens                 PGMINLKGRAKYDAWAKLEGMHAQEAQKNYVELVANLLGK------------ 
Aquabacterium_parvum_beta    PGMMDFVGRAKYDAWAELKGKSQDAAKQAYIDLIESLKK------------- 
Lokiarchaeota_archaeon       PGRLKVKDRAKFDNWESRKGMLKEDAMKAYITLIEKLEQEKK---------- 
Monosiga_brevicollis         PWAVQLEASAKWKAWNSVRGMSKEDAMKAYVDLLAKDDPNWEQHPALKDYKA 
                             *  ..     *:. * . ..   : * : *:  : .                 
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FFAT analysis in ACBD5/Atg37 proteins comparing Fungi and animals based on initial phylogenetic analysis
Group Sub-group Total No No. FFAT score (≤2.5) % FFAT score (≤2.5)
Fungi 56 7 12.50
Animals 37 33 89.19
Vertebrate 20 19 95.00
Invertebrate 17 14 82.35
Analysis focused on additional fungal species 
Order Class Total No. No. FFAT score (≤2.5) % FFAT score (≤2.5)
Basidiomycota 40 2 5.00
Ascomycota 66 18 27.27
Eurotiomycetes 1 1 100.00
Sodaryomycetes 1 0 0.00
Pezizomycetes 6 0 0.00
Orbiliomycetes 2 0 0.00
Dothideomycetes 14 13 92.86
Lecanoromycetes 4 1 25.00
Leotiomycetes 11 0 0.00
Sordariomycotina 6 0 0.00
Xylonomycetes 3 3 100.00
Saccharomycotina 15 1 6.67
Taphrinomycotina 3 0 0.00
Mucoromycota 42 8 19.05
Zoopagomycota 5 1 20.00
Blastocladiamycota 2 0 0.00
Chytridiomycota 6 0 0.00
